Pharmacological validation of a mouse model of L-DOPA-induced dyskinesia

Experimental Neurology

Volumn 194, Issue 1, 2005, Pages 66-75

  Lundblad, M ^a   Usiello, A ^b   Carta, M ^a,c   Hakansson K ^d   Fisone, G ^d   Cenci, M A ^a  

^a LUND UNIVERSITY   (Sweden)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c Sezione di Fisiologia e Nutrizione Umana   (Italy)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

6 OHDA; Dyskinesia; L DOPA; Mouse; Parkinson's disease

Indexed keywords

ADENOSINE A2 RECEPTOR ANTAGONIST; AMANTADINE; BUSPIRONE; DOPAMINE RECEPTOR STIMULATING AGENT; ISTRADEFYLLINE; LEVODOPA; OXIDOPAMINE; RILUZOLE; ROPINIROLE;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DRUG EFFECT; DRUG MEGADOSE; DYSKINESIA; HEAD; INVOLUNTARY MOVEMENT; LIMB; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TRUNK;

ADRENERGIC AGENTS; AMANTADINE; ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; BUSPIRONE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; INDOLES; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; OXIDOPAMINE; PARKINSONIAN DISORDERS; PURINES; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2; REPRODUCIBILITY OF RESULTS; RILUZOLE; TREATMENT OUTCOME;

EID: 19344378522     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2005.02.002     Document Type: Article

References (38)

1. M. Andersson, A. Hilbertson, and M.A. Cenci Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease Neurobiol. Dis. 6 1999 461 474
2. K.E. Asin, L. Bednarz, A. Nikkel, and R. Perner Rotation and striatal c-fos expression after repeated, daily treatment with selective dopamine receptor agonists and levodopa J. Pharmacol. Exp. Ther. 273 1995 1483 1490
3. E. Bezard, J.M. Brotchie, and C.E. Gross Pathophysiology of levodopa-induced dyskinesia: potential for new therapies Nat. Rev., Neurosci. 2 2001 577 588
4. P.J. Blanchet, P. Allard, L. Gregoire, F. Tardif, and P.J. Bedard Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients Can. J. Neurol. Sci. 23 1996 189 193
5. V. Bonifati, E. Fabrizio, R. Cipriani, N. Vanacore, and G. Meco Buspirone in levodopa-induced dyskinesias Clin. Neuropharmacol. 17 1994 73 82
6. M.A. Cenci, and M. Lundblad Utility of 6-hydroxydopamine lesioned rats in the preclinical screening of novel treatments for Parkinson disease M. LeDoux Animal models of movement disorders 2005 Elsevier Academic Press San Diego, CA 193 208
7. M.A. Cenci, M. Andersson, S.E. Daniel, A.E. Kingsbury, L. Kilford, and A.J. Lees Striatal expression of FosB-related transcription factors in human Parkinson's disease: relation to l-DOPA-induced dyskinesia Mov. Disord. 17 Suppl. S 2002 S98
8. M.A. Cenci, I.Q. Whishaw, and T. Schallert Animal models of neurological deficits: how relevant is the rat? Nat. Rev., Neurosci. 3 2002 574 579
9. T.N. Chase Levodopa therapy: consequences of the nonphysiologic replacement of dopamine Neurology 50 1998 S17 S25
10. N.J. Crosby, K.H.O. Deane, and C.E. Clarke Amantadine for dyskinesia in Parkinson's disease (cochrane review) The Cochrane Library 2003 John Wiley and Sons, Ltd Chichester, UK
11. A. Dekundy, M.A. Cenci, and W. Danysz Clinically proven antidyskinetic agents are effective in rat model of l-DOPA-induced dyskinesia Abstr.-Soc. Neurosci. 29 2003 (abstract #757.751)
12. P.R. Dickson, C.G. Lang, S.C. Hinton, and A.E. Kelley Oral stereotypy induced by amphetamine microinjection into striatum: an anatomical mapping study Neuroscience 61 1994 81 91
13. J.P. Doucet, Y. Nakabeppu, P.J. Bedard, B.T. Hope, E.J. Nestler, B.J. Jasmin, J.S. Chen, M.J. Iadarola, M. St-Jean, N. Wigle, P. Blanchet, R. Grondin, and G.S. Robertson Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum Eur. J. Neurosci. 8 1996 365 381
14. J. Gauthier, M. Parent, M. Levesque, and A. Parent The axonal arborization of single nigrostriatal neurons in rats Brain Res. 834 1999 228 232
15. B. Georgievska, D. Kirik, and A. Bjorklund Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer Exp. Neurol. 177 2002 461 474
16. P. Jenner Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates Ann. Neurol. 47 2000 S90 S99 (discussion S99-104)
17. T. Kanda, M.J. Jackson, L.A. Smith, R.K. Pearce, J. Nakamura, H. Kase, Y. Kuwana, and P. Jenner Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys Ann. Neurol. 43 1998 507 513
18. S.J. Kish, K. Shannak, and O. Hornykiewicz Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications N. Engl. J. Med. 318 1988 876 880
19. M. Lundblad, M. Andersson, C. Winkler, D. Kirik, N. Wierup, and M.A. Cenci Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease Eur. J. Neurosci. 15 2002 120 132
20. M. Lundblad, B. Picconi, H. Lindgren, and M.A. Cenci A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function Neurobiol. Dis. 16 2004 110 123
21. R. Marconi, D. Lefebvre-Caparros, A.M. Bonnet, M. Vidailhet, B. Dubois, and Y. Agid Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology Mov. Disord. 9 1994 2 12
22. C. Marin, A. Jimenez, E. Tolosa, M. Bonastre, and J. Bove Bilateral subthalamic nucleus lesion reverses l-DOPA-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats Synapse 51 2004 140 150
23. D. Merims, I. Ziv, R. Djaldetti, and E. Melamed Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease Lancet 353 1999 1764 1765
24. J.G. Nutt, and N.H. Holford The response to levodopa in Parkinson's disease: imposing pharmacological law and order Ann. Neurol. 39 1996 561 573
25. J.A. Obeso, C.W. Olanow, and J.G. Nutt Levodopa motor complications in Parkinson's disease Trends Neurosci. 23 2000 S2 S7
26. J.A. Obeso, M.C. Rodriguez-Oroz, P. Chana, G. Lera, M. Rodriguez, and C.W. Olanow The evolution and origin of motor complications in Parkinson's disease Neurology 55 2000 S13 S20 (discussion S21-13)
27. J.A. Obeso, M. Rodriguez-Oroz, C. Marin, F. Alonso, I. Zamarbide, J.L. Lanciego, and M. Rodriguez-Diaz The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits Neurology 62 2004 S17 S30
28. S.M. Papa, T.M. Engber, A.M. Kask, and T.N. Chase Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration Brain Res. 662 1994 69 74
29. G. Paxinos, and K.B.J. Franklin The mouse brain in stereotaxic coordinates 2001 Academic Press San Diego
30. P. Piccini, R.A. Weeks, and D.J. Brooks Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias Ann. Neurol. 42 1997 720 726
31. B. Picconi, D. Centonze, K. Hakansson, G. Bernardi, P. Greengard, G. Fisone, M.A. Cenci, and P. Calabresi Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia Nat. Neurosci. 6 2003 501 506
32. A. Prikhojan, T. Brannan, and M.D. Yahr Comparative effects of repeated administration of dopamine agonists on circling behavior in rats J. Neural Transm. 107 2000 1159 1164
33. S. Puglisi-Allegra, and S. Cabib Psychopharmacology of dopamine: the contribution of comparative studies in inbred strains of mice Prog. Neurobiol. 51 1997 637 661
34. O. Rascol, D.J. Brooks, A.D. Korczyn, P.P. De Deyn, C.E. Clarke, and A.E. Lang A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group N. Engl. J. Med. 342 2000 1484 1491
35. T. Schallert, and J.L. Tillerson Intervention strategies for degeneration of dopamine neurons in parkinsonism; optimizing behavioural assessment of outcome D.F. Emrich R.L. Dean III P.R. Sandberg Central nervous system diseases: innovative animal models from lab to clinic 2000 Human Press Totowa, NJ 131 151
36. M. Sedelis, R.K. Schwarting, and J.P. Huston Behavioral phenotyping of the MPTP mouse model of Parkinson's disease Behav. Brain Res. 125 2001 109 125
37. H. Towbin, T. Staehelin, and J. Gordon Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications Proc. Natl. Acad. Sci. U. S. A. 76 1979 4350 4354
38. C. Winkler, D. Kirik, A. Bjorklund, and M.A. Cenci l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function Neurobiol. Dis. 10 2002 165 186